Sotera Health Posts Strong Q1 Revenue Growth, Reaffirms 2026 Outlook
SHC sits 48% above its 52-week low of $10.795.
Summary
Sotera Health reported strong first-quarter 2026 financial results, with net revenues for Sterigenics up 9.7% and Nordion up 29.0%, though Nelson Labs saw a slight decrease. The company also reaffirmed its full-year 2026 outlook, projecting net revenues between $1.233 billion and $1.251 billion and Adjusted EPS in the range of $0.93 to $1.01. This positive start to the year and the maintained guidance signal management's confidence in continued operational execution and financial performance, which is a material positive for investors. Traders will be watching for sustained growth across segments and any future adjustments to the reaffirmed guidance.
At the time of this announcement, SHC was trading at $16.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.4B. The 52-week trading range was $10.80 to $19.85. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.